Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) is expected to release its H1 2025 earnings data before the market opens on Wednesday, August 20th. Analysts expect Telix Pharmaceuticals to post earnings of $0.22 per share and revenue of $316.69 million for the quarter.
Telix Pharmaceuticals Trading Down 0.6%
Shares of NASDAQ:TLX opened at $10.82 on Wednesday. Telix Pharmaceuticals has a 52-week low of $10.70 and a 52-week high of $30.36. The business's 50 day moving average is $15.35 and its 200 day moving average is $16.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the company. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. HC Wainwright initiated coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They set a "buy" rating and a $23.00 price objective for the company. Finally, Wedbush reiterated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, June 12th.
View Our Latest Stock Report on TLX
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access